|
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To make an accurate estimation of the association of ERCC1 and ERCC2 polymorphisms with osteosarcoma (OS) prognosis in Chinese population.
|
30544402 |
2018 |
|
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The ERCC2-rs1799793 AA+AC > CC (OR=1.3428, 95% CI=1.0201; 1.7674) had an effect on the risk of osteosarcoma development, whereas, there were no significant associations among the other ERCC SNPs (ERCC1 rs3212986, ERCC1 rs11615, and ERCC2 rs13181) and osteosarcoma.
|
30402838 |
2018 |
|
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ERCC1 (C118T (rs11615) and C8092A (rs3212986)) and ERCC2 (A751C (rs171140) and G312A (rs1799793)) polymorphisms were analysed in 44 patients with osteosarcoma, who were treated with cisplatin based neoadjuvant chemotherapy.
|
29980176 |
2018 |
|
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Some previous studies have sought to investigate the roles of excision repair cross complementation group 1 (<i>ERCC1</i>), <i>ERCC2</i>, <i>ERCC4</i>, and <i>ERCC5</i> gene polymorphisms in the prognosis of osteosarcoma patients.
|
29950854 |
2018 |
|
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis included eleven studies in which four SNPs (ERCC1 rs11615 and rs3212986, ERCC2 rs13181 and rs1799793) reportedly associated with osteosarcoma prognosis were investigated.
|
28977987 |
2017 |
|
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis.
|
28388903 |
2017 |
|
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our findings suggest that ERCC1 rs11615 and ERCC1 rs2298881 genetic polymorphisms are significantly associated with poor response to chemotherapy and unfavourable survival of osteosarcoma.
|
26339355 |
2015 |
|
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In summary, our results suggested that the ERCC1 rs11615 and rs2298881 polymorphisms play important roles in the response to chemotherapy mediated by the DNA repair pathway and in the clinical outcome of osteosarcoma.
|
26345951 |
2015 |
|
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our results suggest that ERCC1 rs11615 polymorphism in the DNA repair pathways play an important role in the response to chemotherapy and overall survival of osteosarcoma.
|
25755792 |
2015 |
|
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our results suggest that the ERCC1 rs11615 polymorphism might influence the response to cisplatin-based chemotherapy and affect the clinical outcome for osteosarcoma patients.
|
26400354 |
2015 |
|
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our results suggest that ERCC1 rs11615 and ERCC2 rs1799793 may be useful genetic prognostic markers for osteosarcoma in a Chinese population.
|
26436406 |
2015 |
|
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We first report associations of four SNPs, ERCC1 Asn118Asn, ERCC1 Gln504Lys, ERCC2 Asp312Asn and ERCC2 Lys751Gln, with risk of death from osteosarcoma in a Chinese population, indicating ERCC1 118T/T and ERCC2 A/A may be used as surrogate markers for clinical outcome of osteosarcoma treatment with cisplatin.
|
23098477 |
2012 |